ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

ABX464 was safe and demonstrated dose-dependent antiviral activity in HIV-infected, treatment-naïve patients

Paris, France January 11th 2016 – 6pm – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced positive top-line efficacy and safety results from the Company’s Phase IIa clinical study (ABX464-003) in patients with HIV infection.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41